OP017: Telemedicine enables a safe shift from examination room based care to personalised care for Inflammatory Bowel Disease: A pragmatic randomised multicenter trial with myIBDcoachECCO'17 Barcelona 2017
1
OP019: Correlation of clinical and endoscopic outcomes in patients with active Crohn’s Disease treated with mongersen (GED- 0301)ECCO'17 Barcelona 2017
1
OP020: Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn DiseaseECCO'17 Barcelona 2017
1
OP021: Hyperbaric oxygen therapy is safe and effective for hospitalised Ulcerative Colitis patients suffering from moderate- severe flares: A multi-center, randomised, double-blind, sham- controlled trialECCO'17 Barcelona 2017
1
OP022: Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in Inflammatory Bowel Diseases: IBD Character studyECCO'17 Barcelona 2017
1
OP023: Maintenance of clinical effect in patients with moderate- to-severe Crohn’s Disease treated with filgotinib, a selective JAK1 inhibitor: Exploratory 20-week data analysis of the Phase 2 FITZROY studyECCO'17 Barcelona 2017
1
OP024: Childhood-onset Inflammatory Bowel Disease and risk of cancer – a Swedish nationwide cohort study 1964-2014ECCO'17 Barcelona 2017
1
OP025: Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn’s Disease in clinical practiceECCO'17 Barcelona 2017
1
OP026: Zero diagnostic yield of dysplasia in polyp adjacent biopsies for patients with Inflammatory Bowel DiseaseECCO'17 Barcelona 2017
1
OP027: IL-33/ST2 axis sustains gut mucosal wound healing and cancerogenesis in Colitis-associated colorectal cancerECCO'17 Barcelona 2017
1
OP028: Gut specific regulatory T cells – a new frontier for Crohn’s Disease therapyECCO'17 Barcelona 2017
1
OP029: Hypoacetylation of histone-3 is a hallmark of intestinal fibrosis in Crohn’s DiseaseECCO'17 Barcelona 2017
1
OP030: Identification of disease-relevant bacterial signatures in gnotobiotic IL-10 deficient mice using fecal samples from IBD patients undergoing hematopoietic stem cell transplantationECCO'17 Barcelona 2017
1
OP031: Long-term safety and tolerability of oral tofacitinib in patients with Crohn’s Disease: Results from a phase 2 open-label 48-week extension studyECCO'17 Barcelona 2017
1
OP032: Efficacy and safety of oral tofacitinib as maintenance therapy in patients with Moderate to Severe Ulcerative Colitis: Results from a phase 3 randomised controlled trialECCO'17 Barcelona 2017
1
OP034: Efficacy and safety of abrilumab in subjects with Moderate to Severe Ulcerative Colitis: Results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled studyECCO'17 Barcelona 2017
1